Navigation Links
Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease

BOSTON, -- Surface Logix Inc. today announced the initiation of a Phase 2a clinical trial for SLx-2101 in patients with secondary Raynaud's disease. SLx-2101 is a novel , long-acting PDE-5 inhibitor being developed for the management of diseases associated with vascular dysfunction such as Raynaud's, a vasospastic disorder of small blood vessels leading to a marked reduction of blood flow to areas such as the fingers and toes. Often triggered by exposure to cold, Raynaud's is associated with painful blue or white digits, and in severe cases, may lead to the development of digital ulcers.

"PDE-5 inhibition holds promise in several cardiovascular indications, though many disorders such as Raynaud's are currently not addressed by marketed PDE-5 inhibitors," commented Paul Sweetnam, Ph.D., Chief Scientific Officer of Surface Logix. "We used our novel chemistry platform to design SLx-2101 to have a profile that would deliver fast onset and long duration of therapeutic effects in difficult-to-treat conditions such as Raynaud's, potentially enabling quicker, longer-lasting relief to patients."

"The initiation of this trial is part of Surface Logix's multiple indication development plan for SLx-2101. We believe that it has applicability in cardiovascular indications beyond erectile dysfunction and are therefore pursuing its advancement in specialized indications, such as Raynaud's, as well as in larger cardiovascular markets," said Jim Mahoney, President and Chief Executive Officer of Surface Logix.

The Phase 2a trial is a single European center, randomized, double-blind, placebo-controlled, crossover pilot study that will enroll 20 patients with secondary Raynaud's disease. The trial is designed to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days. The primary objective of this trial is to investigate the severity of secondary Raynaud's disease-related attacks during the dosing period. Secondary objectives include evaluating the frequency and total daily duration of disease-related attacks during the dosing period, the safety and tolerability of SLx-2101, and the effect of the drug on capillary blood flow velocity and vasospastic symptoms.

Surface Logix also initiated a Phase 2a clinical trial to test the safety, tolerability and pharmacodynamics of orally administered SLx-2101 in patients with hypertension in June 2007. Interim data from a Phase 2a study of SLx-2101 in erectile function confirmed its activity 48 hours after a single dose of 10mg, making it the first PDE-5 inhibitor to confirm such prolonged duration of activity using an objective measure.

Phase 1 studies of SLx-2101 in healthy male volunteers demonstrated its favorable safety, tolerability, pharmacokinetics and pharmacodynamic activity. Additionally, in preclinical animal models, the candidate was highly potent and selective, induced rapid cellular and tissue response and provided an extended duration of action.


'"/>




Related medicine news :

1. Lunar Forces Affect The Surface Of The Earth
2. Controversy Over The Fee Structure In Private Medical Colleges Surfaces Yet Again
3. Meningitis C Surfaces in Toronto:Public Alerted
4. New Study Links Western Wildfires to Atlantic Ocean Surface Temperatures
5. Copper Alloys Surfaces Touted As Pathogen Killers
6. Flesh-eating Bugs Surface in Singapore
7. InfoLogix, Inc. the Leading Healthcare Technology Company SaysHealthcare Informatics
8. Pfizer Commences Its Advertising for Celebrex with All the Warnings
9. Natco Pharma Commences Production At Dehradun Unit
10. Chinas First Gay Health Clinic Commences Operations
11. Mental Health - NHS Trust Commences Specialist Transition Service
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: